# Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation

> **NCT01338987** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 76 (actual)

## Conditions studied

- Myelodysplastic Syndrome
- Acute Lymphocytic Leukemia
- Acute Myelogenous Leukemia
- Chronic Myelogenous Leukemia
- Chronic Myelomonocytic Leukemia

## Interventions

- **PROCEDURE:** First Allogeneic Bone Marrow Transplant (BMT)
- **DRUG:** Leuprolide
- **DRUG:** 18F FLT
- **DRUG:** Cyclophosphamide
- **DRUG:** Methotrexate
- **DRUG:** Tacrolimus
- **RADIATION:** Total Body Irradiation
- **DRUG:** Busulfan
- **DRUG:** Fludarabine
- **PROCEDURE:** Second Allogeneic Bone Marrow Transplantation

## Key facts

- **NCT ID:** NCT01338987
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-19
- **Primary completion:** 2017-12-01
- **Final completion:** 2020-11-19
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2021-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01338987

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01338987, "Pilot Study of Leuprolide to Improve Immune Function After Allogeneic Bone Marrow Transplantation". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01338987. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*